News & Press Releases
June 10, 2020
Novartis presents “Partner of the Year” award to Grünenthal’s manufacturing site in Ecuador: The global healthcare company Novartis has presented its award for “Partner of the Year 2019” to Grünenthal’s site in Quito, Ecuador. The award recognises outstanding quality, efficiency and commitment – and is the company’s most prestigious prize for the best supplier in all categories in the whole Andean Region. Read more
April 16, 2020
Grünenthal hormone production site in Santiago de Chile awarded key Brazilian government certification: Grünenthal’s production site in Santiago de Chile is now certified by ANVISA, the Brazilian Health Regulatory Authority. This success further strengthens Grünenthal’s Contract Manufacturing Business and opens up opportunities to supply hormones and women’s health products in Brazil. Read more
February 15, 2020
Successful FDA inspection for Grünenthal’s manufacturing site in Italy: Our Italian site near Milan has become the second site in Grünenthal’s global manufacturing network to be successfully inspected by the FDA – following our production location in Switzerland. The site passed the inspection with zero findings. This excellent outcome confirms the outstanding quality level maturity and overall quality performance of the Grünenthal manufacturing network. The inspection focused on the biopharma assembly and packaging section of our Italian site. This success will provide the basis for expansion of Grünenthal’s contract manufacturing business.
October 02, 2019
Delighting contract manufacturing customers with a high-tech site in Italy: The team at Grünenthal’s production site in Italy recently hit two important milestones – gaining official approval for the refurbishment of the 2,000-square-metre production hall, as well as for new facilities for its biopharma services. Read more
February 09, 2019
New Medicines Verification System - We protect our patients against falsified pharmaceutical products: As Grünenthal, we are 100 percent committed to supporting the FMD and its aim of increasing safety for patients – and we now have everything in place to bring this legislation to life. We joined forces with partners from across industries through our participation in a working group within the European Federation of Pharmaceutical Industries & Associations (EFPIA), as well as through involvement in the European Medicines Verification Organisation (EMVO) User Group. Read more
July 23, 2018
Grünenthal is setting a new standard in global demand and supply planning capabilities. We have just implemented a new IT solution, SAP Integrated Business Planning, to support the end-to-end IBP process and provide precise and adaptive planning possibilities, automation and seamless data integration. Another major step forward to strengthen our delivery reliability for our Contract Manufacturing Business customers.
June 29, 2018
Today our colleagues in Switzerland celebrate a major milestone: For 25 years they are producing Tramadol in Mitlödi for the global market – this is the world’s largest production unit for Tramadol Hydrochloride. We operate an API-production in top quality: well trained workforce, state of the art facility, precisely controlled processes and efficient Equipment.
May 23, 2018
TECNANDINA, our Manufacturing Site in Ecuador, was honored from Novartis Ecuador with the annual award “Best Logistic Service Supplier in the Andean Cluster”.
Read more: www.tecnandina.com
Interview in World Pharmaceutical Frontiers
January 12, 2017
Grünenthal introduces Latin America’s most modern women’s health products plant Santiago de Chile: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. Read more
December 14, 2016
Grünenthal’s manufacturing site in Ecuador, Tecnandina, receives European GMP certification for the third time: The Grünenthal Group announces today that its manufacturing site in Ecuador, Tecnandina, successfully passed the inspection to manufacture in accordance with the European GMP regulations. The certification covers the production of solid and semi-solid pharmaceuticals for the third time and now, for the first time, also liquid pharmaceuticals. This GMP Certificate will be valid for another three years. Read more
October 1, 2015
Grünenthal receives Brazilian ANVISA certification for Tecnandina production plant in Ecuador: The Grünenthal Group announces that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária, Brazilian Health Surveillance Agency). This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification. Read more